RxDoctor Payments Data

Jorge Fortun, MD

Ophthalmology · Palm Beach Gardens, FLNPI 1184736464

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $504,210 of the $797,682 with a category attached, or 63.2%. It is spread thinly across 29 manufacturers, the largest accounting for just 18.9%. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$797,682in general payments, 2019–2025

Across 679 payments — averaging $1174.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$151K
  • Novartis$127K
  • Astellas Pharma US Inc$104K
  • Alimera Sciences, Inc.$97K
  • Regeneron Healthcare Solutions, Inc.$76K
  • Dutch Ophthalmic, USA$57K
  • plus $187K from 23 others
$147,909in research payments, 2019–2025

Across 20 payments — averaging $7395.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$80K
  • Alimera Sciences, Inc.$36K
  • Novartis$32K

What the payments were for

  • Consulting fees$216,92627%
  • Speaking & faculty fees$504,21063%
  • Travel & lodging$49,7236%
  • Food & beverage$24,7163%
  • Education$1,0500%
  • Entertainment$1,0560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$797,682 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$5,167,142
Medicare patients
1,585
Services billed
81,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate67$3,178
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha55$690
Atropine Sulfate17$593
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$398
Latanoprost31$361

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →